心血管疾病中的ferritinophagy:机制和潜在的治疗方法
Shuyue Wang1, Zengzhao Yu2, Lin Ye1
1School of Basic Medical Sciences, Qingdao University, Qingdao, 266071, China.
Molecular and cellular biochemistry
|June 20, 2025
概括
铁素,即铁素的分解,通过调节铁和细胞死亡,在心血管疾病中至关重要. 了解这个过程为心脏病提供了新的治疗途径.
科学领域:
- 细胞生物学 细胞生物学
- 病理生理学 病理生理学
- 生物化学 生物化学
背景情况:
- 费里替诺法基 (ferritinophagy),即费里的选择性自降解,由核受体协活性剂4 (NCOA4) 介导.
- 这一过程在调节细胞铁平衡和铁亡,一种编程细胞死亡的形式中起着重要作用.
- 新出现的证据突出显示,费里替诺法基参与了各种人类疾病的发病,特别是心血管疾病.
研究的目的:
- 阐明费里丁菌在心血管疾病的发展和进展中的作用.
- 在心脏病的背景下,探索费里替诺法基,铁调节和铁症之间的机械联系.
- 为了确定与心血管疾病治疗的费里替诺法基相关的潜在治疗点.
主要方法:
- 对现有的关于费里丁,NCOA4,铁和心血管疾病的文献进行了审查.
- 分析研究研究铁恒温和反应性氧物种对费里替诺法基和费罗亡的影响.
- 检查临床前和临床数据,将费里水平与心血管病理相关联.
主要成果:
- 费里替诺法基是心血管疾病中铁亡的关键调节者,由NCOA4介导的费里丁降解驱动.
- 通过ferritinophagy增加细胞内铁的释放会加剧ferroptosis,并导致诸如缺血-再输血损伤,动脉样硬化和心力衰竭等疾病.
- 费里水平明显与各种心血管疾病的严重程度有关.
结论:
- 铁代谢是心血管疾病进展的关键途径,影响铁代谢和铁.
- 准费里替诺法基是心血管医学中新型治疗干预的有希望的策略.
- 对费里替诺法基复杂机制及其心脏影响的进一步研究是必要的.
相关概念视频
01:28The Early Endosome: Endocytosis of Transferrin
3.5K
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
3.5K
01:22Heart Failure VI: Adjunct Therapies
39
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
39
01:29Cardiomyopathy V: Interprofessional Care
41
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
41
01:16Necrosis
4.9K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.9K
01:26Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42
01:30Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34